FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
A group of former Pfizer employees have successfully created their own businesses based at and supported by Discovery Park, a thriving life sciences community in Kent.
Read the full article here.
Two of the top 10 largest medtech companies will partner together on robotic head and spine procedures, with Medtronic looking to link its surgical suite with Siemens Healthineers’ pre- and post-op imaging know-how.
Read more here.